-
Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016;6:e011801. pdf -
Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks.
Mastrodima S, Akolekar R, Yerlikaya G, Tzelepis T, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:613-7. pdf -
Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:762-7. pdf -
Contingent screening for preterm pre-eclampsia.
Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:554-9. pdf -
Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy.
Frick AP, Syngelaki A, Zheng M, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:332-9. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
First trimester prediction of HELLP syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenat Diagn 2016;36:29-33. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2016;214:103.e1-103.e12 . pdf -
Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-73. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status.
Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:852-3. -
The influence of parity and gravidity on first trimester markers of chromosomal abnormality.
Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:792-4. -
First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2000;20:683-4. -
The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:673-5. -
First trimester maternal serum AFP and total hCG in aneuploidies other than trisomy 21.
Spencer K, Heath V, Flack N, Ong C, Nicolaides KH.
Prenat Diagn 2000;20:635-9. -
Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Liao AW, Skentou H, Cicero S, Nicolaides KH.
Prenat Diagn 2000;20:495-9. -
The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities.
Spencer K, Ong CY, Liao AW, Nicolaides KH.
Prenat Diagn 2000;20:491-4. -
Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH.
Prenat Diagn 2000;20:411-6. -
Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester.
Spencer K, Tul N, Nicolaides KH.
Prenat Diagn 2000;20:390-4. -
Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy?
Spencer K, Berry E, Crossley JA, Aitken DA, Nicolaides KH.
Prenat Diagn 2000;20:311-7.